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Summary Between 1972 and 1986, 134 patients with stage A carcinoma of the prostate (CAP) were
diagnosed at a single Veterans Administration medical centre and followed annually by the hospital tumour
registry. Seventy-four were classified as stage Al, defined as non-palpable, well-differentiated CAP, regardless
of amount, found unexpectedly on transurethral resection of the prostate (TURP). Twenty-eight were classified
as stage A2, defined as non-palpable, moderately or poorly differentiated CAP, regardless of amount, found
unexpectedly on TURP. The remaining 32 were reclassified as atypical hyperplasia/adenosis (AH/A) rather
than CAP. The survival of each group was compared with the survival of a control group from the same
medical centre who had TURPs showing histologically proven benign prostatic hyperplasia (BPH). Survival
and tumour progression were similar for patients with stage Al CAP, AH/A and BPH. Furthermore, patients
with stage Al CAP, with or without therapy, had similar survivals as patients with BPH in each age group
(under 65, 65-74 and over 74 years). Stage A2 CAP was associated with a significantly worse survival and
more tumour progression. Within stage Al CAP and stage A2 CAP the percentage of chips with CAP or the
amount of CAP removed did not affect survival.
Disease progression and survival in patients with stage A
carcinomas of the prostate (CAP) have been studied by
numerous investigators (Correa et al., 1974; Heaney et al.,
1977; Cantrell et al., 1981; Blute et al., 1986; Epstein et al.,
1986; Johansson et al., 1992; Jones et al., 1992). However, no
study has compared the survival of patients with stage A
CAP with the survival of patients with atypical hyperplasia/
adenosis (AH/A) or patients with benign prostatic hyper-
plasia (BPH) within the same patient population. To clarify
the prognosis of stage A CAP, AH/A and BPH, we com-
pared the long-term survival of patients with Stage A CAP
with patients from the same medical centre who had trans-
urethral resections of the prostate (TURP) showing histo-
logically proven AH/A or BPH.
Materials and methods
All patients with stage A CAP diagnosed at the Veterans
Administration Medical Center, Temple, Texas, USA,
between 1972 and 1986 were identified. Of these, 134 did not
have additional malignancies at the time of diagnosis capable
of influencing survival, and laboratory and radiographic
evaluations at the time of diagnosis did not suggest that the
CAP had metastasised. All 134 had at least a 5 year follow-
up and were followed annually by the hospital tumour regis-
try to the conclusion of the study in 1992. None was lost to
follow-up. Stage A CAP diagnosed in open (suprapubic or
retropubic) prostatectomies were not included because the
surgical procedure, surgical specimen and method of speci-
men handling was different from stage A CAP diagnosed
from TURP tissue.
Stage A CAP was defined as non-palpable carcinoma
found unexpectedly at TURP that showed no evidence of
local extension or metastases on staging work-ups. All his-
tological slides of the 134 stage A CAP specimens were
reviewed, and 102 contained CAP. The remaining 32 con-
tained atypical, non-malignant glandular proliferations which
were reclassified as atypical hyperplasia/adenosis (AH/A)
(Helpap, 1980; Brawn, 1982; McNeal, 1988; Bostwick et al.,
1993) (Figures 1 and 2).
The 102 stage A CAP patients were divided into stage Al,
defined as well-differentiated (WD) CAP, regardless of
amount, and stage A2, defined as moderately differentiated
(MD) or poorly differentiated (PD) CAP, regardless of
amount (Figures 3-5). Within stage A2, it was not possible
to compare the survival of MD and PD CAP because almost
all (25 of 28) of the stage A2 CAP were moderately
differentiated.
The percentage of TURP currettings (chips) containing
CAP was determined by histologically reviewing each case.
The amount of CAP resected was estimated by multiplying
the percentage of chips containing CAP by the weight of the
TURP specimen, which was available in every case. The
result was an estimate of the weight of the TURP chips
containing CAP - not the weight of the CAP.
CAP was graded using a slight modification of the M.D.
Anderson Cancer Center grading system (Brawn et al., 1982).
WD or grade 1 was defined as CAP 75-100% composed of
single, separate malignant glands which were not fused and
did not form cribriform/papillary patterns. PD or grade 4
was defined as 75-100% undifferentiated (non-gland form-
ing). All other patterns were MD or grade 2-3. CAP border-
line between grades 1 and 2-3 or between grades 4 and 2-3
were classified as grade 2-3 in order to maintain the distinct
prognostic significance of grades 1 and 4.
A control group of 134 patients from the same medical
centre was identified by selecting consecutive cases of TURP
showing histologically proven BPH, beginning in January of
each year of the study. None of the control group had
histological evidence of CAP or AH/A. None of the control
group, at the time of their TURP, had additional malignan-
cies capable of influencing survival. In 1992 the hospital
tumour registry determined the status of these 134 patients.
All but six were alive or known to be dead. The six that
could not be contacted had no follow-up after their TURP.
As far as could be determined, these six did not represent
patients whose survival was different from the patients whose
survivals were known.
Patients with TURP showing histologically proven BPH
were selected as the control group because these patients
were of similar age as the patients with stage A CAP and
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AH/A and had the same clinical symptoms as the patients
with stage A CAP and AH/A, i.e. urinary obstruction with-
out palpable abnormality of the prostate. Further, several
studies have demonstrated that patients with histologically
proven BPH are not at increased risk of developing CAP
(Greenwald et al., 1974; Brawn et al., 1993).
Progression of stage A CAP to a higher stage was
documented by biopsy of palpable nodules (stage B), pal-
pable extension of CAP outside the margin of the prostate
(stage C) or documentation of metastases (stage D) by
Figure 1 Mild to moderate atypical hyperplasia/adenosis. The
abnormal glands are somewhat circumscribed and without severe
architectural abnormalities (H&E x 70).
Figure 2 Moderate to severe atypical hyperplasia/adenosis. The
abnormal glands may appear to be 'infiltrating', but infiltration is
difficult to evaluate in an organ where glands and stroma are
normally diffusely blended (H&E x 70).
Figure 3 Well-differentiated (grade 1) carcinoma of the prostate.
Almost all (75- 100%) of the malignant glands are single and
separate with only an occasional suggestion of cribriform/papillary
glands (H&E x 70).
biopsy, unequivocal radiographic evidence or repeatedly
elevated acid phosphatase levels (enzyme methods).
Cancer-specific survival was not utilised since this is a 'soft'
end point which is not perfect even when autopsies are done
on all patients, and is extremely imprecise when autopsies are
not performed (Pretlow, 1994). Survival, which is a 'hard'
end point, was calculated with Kaplan-Meier survival
curves. Differences in survival between groups was assessed
by log-rank tests and proportional hazards regression
models. The Wilcoxon two-sample test was used to compare
extent of tumour in stage Al and A2 CAP, and Fisher's
exact test (two-tailed) was used to assess relative rates of
progression between groups. Statistical analysis was per-
formed using the SAS Statistical Package (SAS Institute,
Cary, NC, USA).
Results
Seventy-four patients were stage Al, 28 were stage A2 and 32
were AH/A. These groups had mean ages of 70, 75 and 68
years with ranges of 50-89, 59-91 and 54-86 respectively.
The control group had a mean age of 66 years with a range
of 41-89. Survival curves (Figure 6) were significantly
different (P<0.0001, chi-square = 42.8, log-rank test,
d.f. = 3) for these groups. Including age in the proportional
hazard model with group did not eliminate the effect of
group (Wald chi-square = 14.0, P = 0.0028), although age
was significantly and negatively associated with survival
(Wald chi-square= 40.1, P<0.0001). Analysis of the
sources of variation among survival curves showed that most
of the difference was due to poorer survival of the A2 group
Figure 4 Moderately differentiated (grade 2-3) carcinoma of the
prostate. About one-half of the malignant glands are single and
separate, while the other half are cribriform/papillary
(H&E x 70).
Figure 5 Moderately differentiated (grade 2-3) carcinoma of the
prostate. About one-half of the malignant glands are single and
separate, while the other half are fused or undifferentiated (non-
gland forming) (H&E x 70).1100 P.N. BRAWN et al.
(chi-square=42.76, d.f.= 1, P<0.0001) with minimal
residual variation between stage A1, AH/A and the control
group (chi-square = 0.067, d.f. = 2, P = 0.96).
Survival curves for Al and A2 patients (Figure 7) with
more or less than the median percentage of chips with CAP
(8.3% for Al and 11.4% for A2) were not significantly
different (P = 0.3 for Al and P = 0.37 for A2, log-rank
tests). Likewise, survival curves for Al and A2 patients
(Figure 8) with more or less than the median resected CAP
volume (1.25 g for Al and 3.30 g for A2) were not
significantly different (P = 0.33 for Al and P = 0.17 for A2,
log-rank tests).
Therapy was provided for 38 of the 74 stage Al CAP
patients (eight hormonal, 25 radiation, one radiation + hor-
monal and four radical prostatectomies), 15 of the 28 stage
A2 CAP patients (nine radiation, five hormonal and one
radiation + hormonal). Association of therapy with survival
was evaluated by a proportional hazards model in which all
forms of therapy were lumped together into a single group.
Therapy was associated with survival in the Al group
(P = 0.04) but not in the A2 or AH/A groups (P = 0.26 and
P = 0.43). When age was included as an additional variable
in the Al group, the association of therapy with survival was
not significant (P = 0.36), while age was highly associated
with survival (P<0.0001), suggesting that the apparent
benefits were due to non-random selection of patients for
therapy. In the AH/A group, age was associated and therapy
was not associated with survival (P = 0.0036 and P = 0.72)
when both variables were included in the model. In the A2
group, neither age (P = 0.32) nor therapy (P = 0.19) was
associated with survival when both variables were included in
the model.
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Figure 6 Survival of patients with stage Al CAP (*), stage A2
CAP (0) or atypical hyperplasia/adenosis (AH/A,O) and a cont-
rol group (A) from the same medical centre who had TURPs
showing histologically proven BPH.
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The stage Al patients and the control group were divided
into three groups by age (under 65, 65-74 and over 74 years)
and their survival compared. There were 26 Al and 56
controls in the under-65 group, 24 Al and 51 controls in the
65-74 group and 24 Al and 21 controls in the over-74
group. Survival curves (Figure 9) and corresponding log-rank
statistics showed no statistical difference in survival in any of
the three groups (P = 0.6767, P = 0.084 and P = 0.38 for the
three age groups).
Progression to a higher stage occurred in four of the 74
stage Al CAP patients vs eight of 28 stage A2 CAP patients,
and was statistically significant (P = 0.003). Although four of
the 32 AH/A patients 'progressed' as compared with four of
74 stage Al CAP patients, this was not statistically
significant (P = 0.24). The control group contained three
patients who were subsequently diagnosed as having CAP.
This 'progression' was not statistically different from patients
in the stage Al group (P = 0.26). (All above statistics are
two-tailed Fisher exact tests.)
Discussion
Stage Al CAP has often been defined as non-palpable WD
or MD CAP found unexpectedly at TURP and involving 5%
or less of the specimen (Correa et al., 1974; Heaney et al.,
1977; Cantrell et al., 1981; Blute et al., 1986; Epstein et al.,
1986; Johansson et al., 1992; Jones et al., 1992). The current
study suggests that a definition of stage Al CAP that relies
only on tumour differentiation has more prognostic
significance. Stage Al CAP, in the current study, was defined
as non-palpable WD CAP, regardless of amount, found
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Figure 8 Survival of patients with stage Al and stage A2 CAP
with more (0) or less (0) than the median amount of resected
cancer volume (weight of TURP chips containing CAP - not
solely the weight of the CAP). Median resected cancer volume for
stage Al and stage A2 is 1.25 g and 3.30 g respectively.
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Figure 7 Survival of patients with stage Al and stage A2 CAP
with more (0) or less (0) than the median percentage of chips
containing CAP. Median percentage of chips containing CAP for
stage Al and stage A2 is 8.3% and 11.4% respectively.
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Figure 9 Survival of stage Al CAP patients (0) compared with
the control group (0) for age ranges of under 65 years, 65-74
years and over 74 years.
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unexpectedly at TURP. The survival of patients with stage
Al CAP, defined in this manner, was similar to the survival
of patients with AH/A and patients with BPH. Stage A2
CAP, defined as non-palpable MD or PD CAP, regardless of
amount, found unexpectedly at TURP, was associated with a
significantly worse survival than stage Al CAP, AH/A or
BPH. Within both stage Al CAP and stage A2 CAP there
was no difference in survival between patients with more or
less than the median percentage of chips with CAP and no
difference in survival between patients who had more or less
then the median amount of CAP removed.
Our understanding of stage A CAP may have been
hindered by studies that included both WD and MD CAP
within stage Al CAP. MD CAP not only implies a more
aggressive lesion but also a larger lesion, since the volume of
CAP increases with dedifferentiation (McNeal et al., 1986;
Brawn, 1992). The current study supported this concept by
finding that MD stage A CAP (stage A2) was associated with
a markedly worse survival than WD CAP (stage A1) and
that MD stage A CAP (stage A2) had a significantly higher
percentage of chips containing CAP and a significantly larger
amount of resected CAP than WD CAP (stage Al). The
grade of CAP is known to dramatically affect prognosis of
other stages of CAP (Brawn et al., 1982; 1990). Conse-
quently, it is not surprising that the prognosis of MD stage A
CAP (stage A2) is significantly different from the prognosis
of WD stage A CAP (stage A1).
It may appear unusual that within stage Al CAP and
within stage A2 CAP the percentage ofchips containing CAP
and the amount of resected CAP did not affect survival.
However, survival is not determined by the amount of CAP
removed. Rather, survival is determined by the amount and
aggressiveness of the CAP remaining in the patient. His-
tological review of TURP tissue allows an estimation of the
grade of the resected CAP but may not be as useful in
estimating the amount of CAP remaining in the patient. In
fact, larger amounts of CAP in the TURP specimen may, in
some cases, improve prognosis ifit indicates that much of the
tumour has been removed.
There are several explanations why patients with stage Al
CAP, as defined in the current study, had similar survivals as
patients with AH/A or patients with BPH. First, autopsy
studies have shown that there is a vast reservoir of small (less
than 1 cm3), non-palpable WD CAP (equivalent to stage Al
CAP) in males over age 50 (McNeal et al., 1986; Brawn et
al., 1991). The vast majority of these CAP do not progress
to stages B, C or D, and even fewer affect survival. The long
indolent course of most stage Al CAP is emphasised by the
finding in the current study that younger men (under age 65)
with stage Al CAP had the same survival as younger men
with histologically proven BPH. Furthermore, the survival of
men with TURP showing AH/A or BPH may be adversely
affected if they have CAP which was not resected surgically,
CAP that was left in the specimen bottle and not studied
histologically or if they develop CAP after their TURP.
Consequently, patient with stage Al CAP have a malignancy
that rarely affects survival, while patients with AH/A or BPH
are not without risk of having their survival adversely
affected by CAP.
An equally plausible explanation for the similar survivals
of patients with stage Al CAP, AH/A and BPH is that some
stage Al CAP are not malignant. A histological diagnosis of
CAP implies that the pathologist is convinced that the lesion
is irrevocably committed to uncontrolled proliferation which
will, given time, metastasise. However, in the opinion of the
authors of this study, it is possible that some 'well-
differentiated' CAP are, in fact, reversible lesions which will
regress with time or are stagnant lesions without the ability
to proliferate in an uncontrolled manner and eventually
metastasise.
Slightly over one-half of the stage Al and A2 patients in
the current study received therapy. Most therapy was radia-
tion and/or hormonal, and only four patients had radical
prostatectomies. Stage Al patients receiving therapy were
younger and had a better survival than those not receiving
therapy. However, when analysed, age, not therapy, cor-
related best with survival. At any given age, stage Al
patients had similar survivals, with or without therapy, as
patients with histologically proven BPH. In contrast, age did
not affect the survival ofpatients with stage A2 CAP because
the overriding factor in these cases was the aggressiveness of
stage A2 CAP.
Progression of stage Al CAP will vary from study to study
depending on the thoroughness of follow-up. Furthermore,
some patients with stage Al CAP as well as some patients
with AH/A or BPH will die of CAP. However, the results of
this study suggest that patients with stage Al CAP, with or
without therapy, regardless of the percentage of chips con-
taining CAP or the amount of CAP removed at TURP, have
an equivalent survival, in each age group, as patients with
histologically proven BPH and an overall survival similar to
patients with AH/A.
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